Patients from 22+ countriesPlan your visit →
lutetium-therapy
Caregiver Treatment Decisions · 14 Sept 2026

Coordinating Your Parent's Lu-177 PSMA Treatment in India

If your parent has mCRPC and someone has mentioned Lu-177 PSMA therapy in India as a possible next step, this eight-step checklist walks you through every coordination task - from gathering the right scans to managing radiation safety at home between cycles.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 14 Sept 2026
Coordinating Your Parent's Lu-177 PSMA Treatment in India

This article is for adult children and family members coordinating a parent's Lu-177 PSMA treatment in India. Your parent likely has metastatic castration-resistant prostate cancer, or mCRPC - a stage where cancer has spread beyond the prostate and stops responding to standard hormone therapy. You've heard about lutetium Lu 177 vipivotide tetraxetan, sometimes called Pluvicto, and want to move from research to planning. This checklist covers the full process: confirming eligibility and gathering documents, each treatment cycle, and home monitoring.

Lu-177 PSMA therapy is a type of radioligand therapy. A radioactive substance attaches to a molecule that finds PSMA - prostate-specific membrane antigen - a protein on most prostate cancer cells. When it binds to PSMA, it delivers radiation directly to the tumor. The U.S. Food and Drug Administration first approved this treatment in March 2022 for men with PSMA-positive mCRPC who had received certain prior therapies, and has since expanded that approval. India has well-established nuclear medicine centers offering this therapy, often at much lower cost than in the United States.

What Does the Coordination Process Look Like - Step by Step?

  1. Confirm the mCRPC diagnosis and treatment history in writing.
  2. Get a PSMA-PET/CT scan done, or gather existing PSMA-PET images from the past 2-3 months.
  3. Collect recent blood work - full blood count, kidney function, and liver function tests.
  4. Request a remote eligibility review before booking any flights.
  5. Apply for an Indian medical visa once eligibility is confirmed and a slot is booked.
  6. Plan the full treatment timeline around the 4-to-6-cycle schedule.
  7. Set up radiation-safe accommodation for the days immediately after each infusion.
  8. Brief your home oncologist and arrange local monitoring between cycles.

Does Your Parent Actually Qualify?

Not every man with advanced prostate cancer is eligible for Lu-177 PSMA therapy. Eligibility depends on specific imaging findings and clinical values. The criteria below are from the VISION trial - the study that got FDA approval - and are used by nuclear medicine programs in India and worldwide.

  • PSMA-positive PET scan. At least one lesion must show PSMA uptake above the level seen in the liver on a PSMA-PET/CT scan. If PSMA expression is low or absent, the therapy may not work. Some patients have both PSMA-negative and PSMA-positive lesions, which the team weighs carefully.
  • Confirmed mCRPC. Testosterone must be at castrate levels - typically below 50 ng/mL - while on androgen deprivation therapy, and the cancer must be progressing despite that suppression.
  • Adequate kidney function. An estimated glomerular filtration rate (eGFR) of at least 60 mL/min is typically required. The kidneys filter out the radioactive substance, so they need to be functioning well before and during treatment.
  • Adequate blood counts. The team checks hemoglobin, platelet count, and neutrophil count before each cycle. Values that are too low may delay or rule out treatment.
  • Reasonable physical condition. Most programs require a performance status of ECOG 0 or 1 - meaning your parent is either fully active or has some limitations but can largely care for himself day to day.
  • Prior treatment history. In the original approval, patients needed prior taxane chemotherapy and androgen receptor pathway inhibition. Eligibility criteria have since expanded, so your parent's specific treatment history matters. Confirm this directly with the nuclear medicine team based on current guidelines.

What Records Should You Gather Before the First Consultation?

A remote eligibility review depends entirely on having the right documents. Without them, the nuclear medicine team cannot give you a reliable answer. Collect the following before contacting any hospital.

  • Pathology report. The original biopsy report confirming prostate cancer, including the Gleason score or Grade Group.
  • PSMA-PET/CT scan images. Ideally from within the past 2-3 months. The actual DICOM image files on a disc or via digital transfer are far more useful than a written summary alone. If your parent has not yet had a PSMA-PET scan, ask the local oncologist for a referral to a nuclear medicine center that offers this scan with 68Ga-PSMA-11 or an equivalent approved tracer.
  • PSA history. A table or list of prostate-specific antigen (PSA) values over time. A rising PSA trend despite castrate testosterone confirms the castration-resistant nature of the disease.
  • Testosterone level results. A recent confirmed result showing castrate levels on androgen deprivation therapy.
  • Prior treatment records. Names and dates of all hormone therapies tried, reasons for stopping, and - if chemotherapy was given - the regimen name, number of cycles, and outcome.
  • Recent blood work. Full blood count, kidney function (creatinine or eGFR), and liver function tests within the past 4-6 weeks.
  • Any bone or CT scans. These help the team understand how far the cancer has spread and whether there are large lesions near the kidneys, spinal cord, or other structures that affect the treatment plan.
  • Full medication list. All current medications and supplements. Some may need to be paused before treatment begins, and the team needs to know about interactions.

Why a Remote Eligibility Review Must Come Before Flights

Do not book flights until you have a remote eligibility review in hand. Some patients travel to India and are told after arriving that their PSMA-PET scan does not show enough uptake, or that their kidney function is below the threshold required for safe treatment. A teleconsultation - where you share scans and records digitally before anyone travels - keeps your family from that outcome. You can send your PSMA-PET report to the Art of Healing Cancer team for review as a first step. If the team does not confirm eligibility, they can give honest guidance on what alternatives may be worth discussing with your oncologist at home.

Our dedicated guide to getting a Lu-177 PSMA second opinion before your India flight covers what to include in that submission and what questions to ask before committing to travel.

Applying for an Indian Medical Visa

Once the team confirms your eligibility and books a treatment slot, your parent will need an Indian e-Medical Visa, known as an e-MV. This visa category lets patients come to India for medical treatment. Here is what the application typically requires.

  • A letter from the Indian hospital confirming the treatment, the hospital name, and the expected treatment dates. The hospital's international patient desk provides this letter once a slot is booked.
  • The e-MV application, submitted through the Indian government e-visa portal. The visa can often be issued for multiple entries, which matters if your parent plans to fly home between cycles.
  • One companion can apply on a linked medical attendant visa. Coordinate this with the hospital at the time of booking - they are familiar with this process for international families.
  • Proof of accommodation and sufficient funds for the stay.

Processing times vary by country and season. Apply at least 3-4 weeks before you plan to arrive. Keep the hospital confirmation letter with the visa documents when traveling - immigration officers may ask about the purpose of the visit.

How Should You Plan the Treatment Timeline?

Lu-177 PSMA therapy is not a single appointment. The standard course in the VISION trial involved up to 6 cycles, each about 6 weeks apart. Depending on how many cycles your parent receives and how the cancer responds, the full course takes roughly 5 to 7 months. You have two practical options for managing this schedule.

  • Stay in India for the full course. This avoids repeated long-haul flights, which can be very tiring for older patients. Many families rent serviced apartments or stay at hospital-recommended guesthouses close to the treatment center. The trade-off is a long continuous stay away from home.
  • Fly home between cycles. If the flight from your home country to India is manageable - ideally under 8-10 hours with a straightforward connection - many families return home for 4-5 weeks between each infusion and travel back for the next one. This keeps the patient in familiar surroundings for most of the treatment period.

Ask the hospital to provide a written cycle schedule in advance, with approximate dates for each infusion. This helps you plan visas, accommodation, and work leave. Ask also about the policy for rescheduling if your parent is unwell on a planned infusion date - cycles can sometimes be shifted by a week or two without compromising the overall treatment course.

What Happens on Infusion Day?

Each cycle involves a single intravenous infusion of lutetium Lu 177 vipivotide tetraxetan. The infusion usually takes about 30 minutes. Your parent will remain in hospital for several hours afterward while the team monitors for any immediate reactions. Published guidance on best care practices for PSMA-targeted radiopharmaceutical therapy describes the monitoring protocols and radiation protection measures the team follows throughout this period. Most patients feel well enough to return to their accommodation the same evening.

Common effects in the days after infusion include fatigue and mild nausea. These tend to ease before the next cycle. For a full walkthrough of what your parent is likely to experience, see our article on what to expect during your first Lu-177 PSMA cycle.

What Are the Radiation Safety Rules at Home After Each Infusion?

After receiving Lu-177 PSMA therapy, your parent's bodily fluids carry trace levels of radioactivity for a short period. The precautions are practical and manageable. Published guidance on radiation safety logistics for PSMA therapy programs recommends the following for approximately 3 days after each infusion.

  • Separate bathroom use. If possible, your parent should use a dedicated toilet during this period. If that is not an option, clean the toilet seat and flush twice after each use.
  • Sit down to urinate. This reduces splashing. The bulk of the radioactive material leaves the body through urine in the first few days.
  • Gloves when handling soiled laundry. Clothing or bedding soiled with urine, vomit, or stool should be handled with disposable gloves, then washed promptly and separately from other laundry.
  • Distance from children and pregnant women. Keep approximately 1 metre of distance from young children and anyone who is pregnant for at least the first 3 days after each infusion.
  • Separate sleeping arrangements. Your parent should sleep in a separate bed for the first 2-3 nights. The treating team will give specific written guidance based on your parent's dose.

The hospital will provide written radiation safety instructions before discharge. Keep these with you if your family plans to fly home within a day or two of an infusion - show this document to security or airline staff if they ask.

Coordinating Monitoring with the Home Oncologist

Keep your parent's home oncologist informed throughout the treatment course. Before traveling, share the plan with the local team and confirm they are willing to coordinate follow-up care. After each cycle, you will need three things.

  • A treatment summary from the Indian hospital, in English, stating the cycle number, dose administered, and any side effects recorded during the admission.
  • A PSA test and full blood count, about 4-6 weeks after each infusion. These can be done at any local laboratory or clinic in your home country.
  • A follow-up imaging plan. Most treating teams order a PSMA-PET or CT scan after 2-3 cycles to assess how the cancer is responding to treatment.

Share all local results electronically with the Indian treating team before each subsequent cycle. They review PSA trends and blood count values as part of deciding whether to continue, change, or stop the course.

Supporting Your Parent - and Yourself - Between Cycles

The weeks between cycles are when coordination often feels most uncertain. Your parent may feel tired, eat less, or have bone pain. Report these to the treating team, and manage them with good food, water, and rest. Many caregivers find their own sleep disrupted during a long treatment course like this. If you need help with sleep or stress, talk to your doctor about what's available.

What If Your Parent Turns Out Not to Be Eligible?

This is a real possibility. Discuss it honestly before you commit time and money to the process. If the PSMA-PET scan doesn't show enough PSMA, or if kidney function or blood counts fall below safe levels, the team may say no to Lu-177 PSMA treatment. In that case, ask for a clear explanation of what other options exist. A remote review prevents you from traveling thousands of miles just to find out the answer is no.

If treatment isn't an option for your parent, our guide covers next steps and what to ask your doctor at home.

When to Talk to Your Doctor

Talk to your parent's oncologist soon if you are thinking about this treatment. Ask if your parent has had a PSMA-PET scan and if it showed enough PSMA. Ask also about current kidney function and blood count values, since these are part of eligibility alongside the imaging. To request a remote review of your parent's scans and treatment history, use the Lutetium Therapy contact form. If Lu-177 PSMA doesn't work for your parent, ask what other options you should discuss with your oncologist.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Can my parent's PSMA-PET scan be done locally before we travel to India?

Yes, and it is preferable to have the scan done at home first. This allows the Indian treating team to review the images remotely and confirm eligibility before any flights are booked. The scan should ideally be done within 2-3 months of the planned treatment date. Ask your parent's oncologist for a referral to a nuclear medicine center that offers PSMA-PET/CT with 68Ga-PSMA-11 or a comparable approved tracer. Bring the DICOM image files on a disc or arrange digital transfer - a written report alone is not sufficient for a full eligibility review.

How many trips to India will our family need to make for a full treatment course?

A standard course involves 4 to 6 cycles, each spaced approximately 6 weeks apart. If you fly home between every cycle, that means 4 to 6 separate trips. Many families from distant countries - particularly in Africa or the Gulf - choose to stay in India for the entire course rather than make repeated long-haul journeys. Families with shorter or more direct flight routes often find it manageable to return home between cycles. Discuss the options with the hospital's international patient desk early, so accommodation and visa planning can be done in advance for whichever approach suits your family.

Is it safe to fly home a few days after an infusion?

Most hospitals clear patients to travel by air once the initial radiation precaution period - typically around 3 days - has passed. The treating team will give you a radiation safety card or letter explaining the situation and the precautions in place. This document is useful to carry at airport security. Confirm the exact recommended waiting period with the treating team before booking any return flight that falls close to an infusion date. Do not assume a standard interval - the team will give guidance specific to your parent's dose and circumstances.

What if my parent does not qualify for Lu-177 PSMA therapy?

If the PSMA-PET scan shows low or absent PSMA expression, or if kidney function or blood counts are not adequate, the treating team will explain why and discuss what alternatives may be available. This is exactly why a remote review before travel matters - it avoids a situation where your family flies to India only to be told your parent is not a suitable candidate. If eligibility is not confirmed, ask for a written explanation of the reason and a clear conversation about what other treatment options may apply to your parent's specific situation.

Can we monitor PSA and blood counts between cycles in our home country?

Yes. PSA tests and blood count checks can be done at any laboratory or clinic in your home country. The Indian hospital will give you a monitoring schedule after each cycle - typically a PSA check and full blood count around 4-6 weeks post-infusion. Share the results electronically with the Indian treating team before each subsequent cycle. They use this information to assess how the cancer is responding and whether there are any safety concerns before administering the next dose.

What documents does the hospital need to confirm a treatment slot?

Hospitals typically need the PSMA-PET/CT images in DICOM format, the written radiology report, recent blood work (full blood count, kidney function, liver function tests), a PSA history, the original pathology report, and a brief letter from the current oncologist summarizing the treatment history. Some hospitals also request a copy of the passport and a completed intake form. The hospital's international patient coordinator will send you a specific document checklist when you first make contact, so ask for it early in the process.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA India: Caregiver Coordination Checklist | lutetium-therapy